Metformin
Small molecule targets CFTR, CXCL1, FAP, MMP9, MTOR, SLC19A3 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 7 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Refused (EMA) | EU (EMA) | Janumet | — | 2009-02-18 | europa.eu ↗ |
| Approved | EU (EMA) | Avandamet | — | 2003-10-20 | europa.eu ↗ |
| Label expansions (4) | US (FDA) | GLUCOPHAGE | — | 1998-10-22 – 2001-04-19 | fda.gov ↗ |
| Approved | US (FDA) | GLUCOPHAGE | — | 1995-03-03 | fda.gov ↗ |
Trials 1,173 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 042 trials · 1 missed | ||||||
| Phase 0 | NCT07699367 | Nov 2026 → Oct 2031 expected | muscular atrophy | University of Utah | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07588932 | May 2026 → Dec 2027 expected | stroke disorder | Spaulding Rehabilitation Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT07120971 | Dec 2025 → Sep 2028 expected | bronchopulmonary dysplasia | Medical College of Wisconsin | Recruiting | No outcome recorded |
| Phase 0 | NCT07065591 | Oct 2025 → Apr 2028 expected | osteoarthritis, knee | The University of Hong Kong | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07179042 | Sep 2025 → Sep 2030 expected | muscular atrophy | University of Utah | Enrolling by invitation | No outcome recorded |
| Phase 0 | NCT06185179 | Sep 2024 → May 2029 expected | muscular atrophy | University of Utah | Recruiting | No outcome recorded |
| Phase 0 | NCT06120881 | Apr 2024 → Dec 2026 expected | type 2 diabetes mellitus | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 0 | NCT05680662 | Jan → Dec 2023 | female breast carcinoma, triple-negative breast carcinoma | Ministry of Health, Saudi Arabia | Unknown | No outcome recorded |
| Phase 0 | NCT05349474 | Apr 2022 → May 2025 | primary progressive multiple sclerosis, secondary progressive multiple sclerosis | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 0 | NCT05365451 | Apr 2022 → Jul 2023 | — | Washington State University | Completed | No outcome recorded |
| Phase 0 | NCT05262257 | Apr 2022 → Dec 2023 | type 2 diabetes mellitus | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 0 | NCT03905941 | Aug 2021 → Nov 2024 | polycystic ovary syndrome | University of Virginia | Withdrawn | No outcome recorded Stop: Business |
| Phase 0 | NCT04204044 | Nov 2020 → May 2021 | polycystic ovary syndrome | Rashid Latif Medical College | Unknown | No outcome recorded |
| Phase 0 | NCT06628544 | Sep 2020 → Aug 2023 | — | Zhongnan Hospital | Completed | No outcome recorded |
| Phase 0 | NCT03107884 | Aug 2019 → Nov 2026 expected | muscular atrophy | University of Utah | Active not recruiting | No outcome recorded |
| Phase 0 | NCT03618654 | Nov 2018 → Nov 2021 | oral cavity squamous cell carcinoma, oropharynx squamous cell carcinoma | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Completed | No outcome recorded |
| Phase 0 | NCT03445702 | Oct 2018 → Oct 2020 | type 2 diabetes mellitus | St. Louis University | Completed | No outcome recorded |
| Phase 0 | NCT03916263 | Aug 2018 → Oct 2022 | polycystic ovary syndrome | Texas Tech University Health Sciences Center | Completed | No outcome recorded |
| Phase 0 | NCT03477162 | May 2018 → Nov 2021 | neoplasm of thorax | Dartmouth-Hitchcock Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT03378297 | May 2018 → Jan 2023 | ovarian cancer | Haukeland University Hospital | Completed | No outcome recorded |
| Phase 0 | NCT03772262 | Apr → Nov 2018 | — | Washington State University | Completed | No outcome recorded |
| Phase 0 | NCT03151772 | Jan 2018 → Sep 2020 | glioblastoma | Sahlgrenska University Hospital | Terminated | No outcome recorded |
| Phase 0 | NCT03117517 | Mar → Aug 2017 | polycystic ovary syndrome | Khyber Medical University Peshawar | Completed | No outcome recorded |
| Phase 0 | NCT01422746 | Mar 2017 → Dec 2024 | obesity disorder, polycystic ovary syndrome | University of Virginia | Unknown | No outcome recorded |
| Phase 0 | NCT02981329 | Mar 2017 → Jul 2020 | sickle cell disease | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 0 | NCT03109873 | Jan 2017 → Jul 2020 | laryngeal disorder, oral cavity cancer, pharynx neoplasm | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Completed | No outcome recorded |
| Phase 0 | NCT02823691 | Apr 2016 → Dec 2021 | neuroendocrine neoplasm | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Unknown | No outcome recorded |
| Phase 0 | NCT02498522 | Aug 2015 → Feb 2016 | polycystic ovary syndrome | Ain Shams University | Completed | No outcome recorded |
| Phase 0 | NCT02587741 | Jul 2015 → Jul 2023 | diabetic retinopathy | Third Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 0 | NCT02153450 | May 2015 → Aug 2018 | pancreatic acinar cell carcinoma, pancreatic ductal adenocarcinoma | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT02308228 | Jan 2015 → Dec 2017 | — | Philip Kern | Completed | Missed primary |
| Phase 0 | NCT02402348 | Dec 2014 → Aug 2016 | head and neck cancer | West Virginia University | Terminated | No outcome recorded Stop: Business |
| Phase 0 | NCT02184832 | Aug 2014 → Mar 2016 | — | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 0 | NCT01980823 | Oct 2013 → May 2018 | breast cancer | Columbia University | Completed | No outcome recorded |
| Phase 0 | NCT02083692 | Sep 2013 → May 2016 | head and neck squamous cell carcinoma | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Completed | No outcome recorded |
| Phase 0 | NCT01793948 | Apr 2013 → Jan 2018 | breast cancer, obesity disorder | Anna Maria Storniolo | Completed | No outcome recorded |
| Phase 0 | NCT01685762 | Jan 2013 → Dec 2015 | endometrial hyperplasia without atypia | UNC Lineberger Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT01911247 | May 2011 → Feb 2013 | endometrial cancer | UNC Lineberger Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT01302002 | Jan 2011 → Feb 2016 | breast cancer | Brazilian National Cancer Institute | Withdrawn | No outcome recorded |
| Phase 0 | NCT01205672 | Sep 2010 → May 2017 | endometrial cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT01465113 | May 2010 → Feb 2016 | Barrett esophagus | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT01037660 | Sep 2005 → Dec 2015 | cardiovascular disorder | Boston University | Completed | No outcome recorded |
| Phase 1318 trials · 17 met primary · 1 missed | ||||||
| Phase 1 | NCT07511010 | Oct 2026 expected | type 2 diabetes mellitus | Chipscreen Biosciences, Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07796191 | Sep → Nov 2026 expected | — | Jiangsu vcare pharmaceutical technology co., LTD | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07275359 | Sep 2026 → Sep 2028 expected | chronic obstructive pulmonary disease | Duke University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07300059 | Jul → Aug 2026 overdue | — | Aspargo Labs, Inc | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07300046 | Jun → Aug 2026 overdue | — | Aspargo Labs, Inc | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07396844 | Jun 2026 | — | LG Chem | Completed | No outcome recorded |
| Phase 1 | NCT07570082 | May → Dec 2026 expected | — | Crinetics Pharmaceuticals Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07550816 | May → Dec 2026 expected | obesity disorder | Beijing QL Biopharmaceutical Co.,Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT07567781 | Apr → Jul 2026 overdue | — | AbbVie | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07530289 | Apr → May 2026 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Show all 318 trials opens the full record — a long page | ||||||
| Phase 1/235 trials · 2 met primary | ||||||
| Phase 1/2 | NCT07666698 | Jul 2026 → Jul 2028 expected | heart failure | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07395960 | Sep 2025 → Sep 2026 overdue | cognitive impairment with or without cerebellar ataxia, obesity disorder | Fudan University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06871904 | Apr → Dec 2025 | oral submucous fibrosis | Ziauddin University | Completed | No outcome recorded |
| Phase 1/2 | NCT06845540 | Feb → May 2025 overdue | hyperpigmentation of the skin | University of Puerto Rico | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06332612 | Aug → Dec 2024 | oral submucous fibrosis | Ziauddin University | Completed | No outcome recorded |
| Phase 1/2 | NCT06030622 | Apr → Dec 2024 | malignant pancreatic neoplasm | State University of New York - Downstate Medical Center | Unknown | No outcome recorded |
| Phase 1/2 | NCT06090227 | Dec 2023 → Nov 2027 expected | focal segmental glomerulosclerosis | Yale University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05768139 | Apr 2023 → Jul 2030 expected | breast cancer | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05759312 | Mar 2023 → Feb 2025 | ovarian clear cell cancer | Fudan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT05036226 | Mar 2022 → May 2027 expected | prostate cancer | Medical University of South Carolina | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04767841 | Feb 2021 → Jun 2024 | osteoarthritis, knee | Sadat City University | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT04530747 | Jan → Nov 2021 | obstructive sleep apnea syndrome | Pennington Biomedical Research Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT04545736 | Nov 2020 → Feb 2028 expected | ABCA4-related retinopathy, Stargardt disease | National Eye Institute (NEI) | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04536805 | Nov 2020 → Nov 2031 expected | prostate cancer | Institut Cancerologie de l'Ouest | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04377451 | Jul 2020 → Jun 2023 | dengue disease, obesity disorder, phenformin 4-hydroxylation | Oxford University Clinical Research Unit, Vietnam | Completed | No outcome recorded |
| Phase 1/2 | NCT04121468 | Feb 2020 → Mar 2027 expected | multiple sclerosis | The Hospital for Sick Children | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04268563 | Jan 2020 → Jul 2021 | infertility disorder, polycystic ovary syndrome | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 1/2 | NCT04141163 | Oct 2019 → Mar 2021 | fragile X syndrome | Rowan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04068246 | Aug 2019 → Dec 2020 | rheumatoid arthritis | Sadat City University | Completed | No outcome recorded |
| Phase 1/2 | NCT03772964 | Jan 2019 → Mar 2020 | inflammatory disease | Brian Zuckerbraun | Completed | No outcome recorded |
| Phase 1/2 | NCT03757923 | Jun → Dec 2018 | menstrual disorder | Dow University of Health Sciences | Unknown | No outcome recorded |
| Phase 1/2 | NCT03424005 | Mar 2018 → Sep 2030 expected | breast cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02949700 | Jan 2017 → Jun 2021 | head and neck squamous cell carcinoma | Baylor College of Medicine | Completed | Met primary |
| Phase 1/2 | NCT04088448 | Jan 2017 → Jun 2020 | major depressive disorder | Sadat City University | Completed | No outcome recorded |
| Phase 1/2 | NCT02496741 | Nov 2015 → Nov 2019 | chondrosarcoma, glioma, intrahepatic cholangiocarcinoma | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
| Phase 1/2 | NCT02495103 | Aug 2015 → Feb 2020 | leiomyomatosis, renal cell carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1/2 | NCT02143050 | Sep 2014 → Nov 2017 | melanoma | University of Louisville | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT02179788 | Jun 2014 → Jul 2016 | lactation disease, prediabetes syndrome | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 1/2 | NCT01804842 | Dec 2012 → Apr 2013 | type 2 diabetes mellitus | Elcelyx Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01638676 | Jul 2012 → Jun 2025 overdue | melanoma | University of Louisville | Recruiting | No outcome recorded |
| Phase 1/2 | NCT01677299 | May → Sep 2012 | type 2 diabetes mellitus | Elcelyx Therapeutics, Inc. | Completed | Met primary |
| Phase 1/2 | NCT01488552 | Nov 2011 → Aug 2015 | pancreas disorder | Pancreatic Cancer Research Team | Completed | No outcome recorded |
| Phase 1/2 | NCT00390273 | Dec 2006 → Oct 2007 | lactic acidosis | Centre de Recherche en Nutrition Humaine Rhone-Alpe | Completed | No outcome recorded |
| Phase 1/2 | NCT00425009 | Jan → Dec 2004 | type 2 diabetes mellitus | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 1/2 | NCT01084486 | — | NAFLD1 | Wolfson Medical Center | Completed | No outcome recorded |
| Phase 2244 trials · 11 met primary · 25 missed | ||||||
| Phase 2 | NCT07647003 | Oct 2026 → May 2027 expected | hypertensive disorder | NuSirt Biopharma | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07139405 | Sep 2026 → Sep 2027 expected | type 2 diabetes mellitus | Myopharm Limited | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07007221 | Jul 2026 → Dec 2030 | HIV infectious disease, depressive disorder | University of Minnesota | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT07693452 | Jun 2026 → Feb 2028 expected | pseudomyxoma peritonei | University of California, Irvine | Recruiting | No outcome recorded |
| Phase 2 | NCT07226453 | May 2026 → Apr 2028 expected | posterior fossa group A ependymoma | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 2 | NCT07291297 | Mar 2026 → Oct 2028 expected | soft tissue sarcoma | Wake Forest University Health Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT07387900 | Feb 2026 → Sep 2027 expected | oral mucosa leukoplakia | Cairo University | Recruiting | No outcome recorded |
| Phase 2 | NCT07129473 | Jan 2026 → Jan 2030 expected | hyperemesis gravidarum | University of Southern California | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06463743 | Sep 2025 → Jan 2027 expected | multiple sclerosis | State University of New York at Buffalo | Recruiting | No outcome recorded |
| Phase 2 | NCT05607316 | Jul 2025 → Jun 2028 | vitiligo | University of Massachusetts, Worcester | Withdrawn | No outcome recorded Stop: Business |
| Show all 244 trials opens the full record — a long page | ||||||
| Phase 2/327 trials · 2 met primary · 3 missed | ||||||
| Phase 2/3 | NCT07033585 | Jun 2025 → Oct 2026 expected | type 2 diabetes mellitus | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT07092618 | Dec 2024 → Aug 2025 overdue | — | AgelessRx | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06691542 | Nov 2024 → Mar 2025 overdue | verrucous papilloma | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06080802 | Nov 2023 → Nov 2024 | diastolic heart failure, type 2 diabetes mellitus | October University for Modern Sciences and Arts | Unknown | No outcome recorded |
| Phase 2/3 | NCT06766201 | Aug 2023 → Sep 2024 | periodontitis | Postgraduate Institute of Dental Sciences Rohtak | Completed | No outcome recorded |
| Phase 2/3 | NCT05373680 | Jan 2022 → Apr 2024 | chronic kidney disease | Tanta University | Completed | Met primary |
| Phase 2/3 | NCT04409795 | Aug 2021 → Dec 2024 | monogenic diabetes, type 1 diabetes mellitus | Joslin Diabetes Center | Completed | No outcome recorded |
| Phase 2/3 | NCT04098666 | Mar 2021 → Apr 2026 overdue | cognitive impairment with or without cerebellar ataxia | Columbia University | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT05638893 | Feb 2021 → Mar 2022 | osteoarthritis, knee | Tanta University | Completed | No outcome recorded |
| Phase 2/3 | NCT04607252 | Jan → Jun 2021 | atypical endometrial hyperplasia | Fudan University | Terminated | No outcome recorded |
| Phase 2/3 | NCT04387630 | Jun 2020 → Jun 2022 | breast cancer | Mansoura University | Unknown | No outcome recorded |
| Phase 2/3 | NCT03452267 | Sep 2019 → Dec 2024 | — | Wayne State University | Withdrawn | No outcome recorded Stop: Business |
| Phase 2/3 | NCT04500678 | Feb 2019 → Feb 2022 | HIV infectious disease | University of Hawaii | Unknown | No outcome recorded |
| Phase 2/3 | NCT03129113 | Mar 2017 → Nov 2020 | HIV infectious disease, fatty liver disease | University College, London | Completed | No outcome recorded |
| Phase 2/3 | NCT02882477 | Dec 2016 → May 2018 | diabetes mellitus, iron metabolism disease, optic atrophy, peptic ulcer disease +2 | Hadassah Medical Organization | Unknown | No outcome recorded |
| Phase 2/3 | NCT03981861 | Jul 2016 → Jul 2018 | polycystic ovary syndrome | Children's Mercy Hospital Kansas City | Completed | No outcome recorded |
| Phase 2/3 | NCT02065687 | Mar 2014 → Apr 2019 | endometrial clear cell adenocarcinoma, endometrial serous adenocarcinoma, endometrial undifferentiated carcinoma | Gynecologic Oncology Group | Unknown | No outcome recorded |
| Phase 2/3 | NCT01690091 | Nov 2012 → May 2016 | heart failure | Institute for Clinical and Experimental Medicine | Completed | No outcome recorded |
| Phase 2/3 | NCT01319994 | Jul 2012 → Aug 2014 | exogenous Cushing syndrome | Barts & The London NHS Trust | Completed | Missed primary |
| Phase 2/3 | NCT01217307 | Jan 2011 → Oct 2013 | ST-elevation myocardial infarction, coronary artery disorder, diabetes mellitus, heart failure | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 2/3 | NCT01855763 | Dec 2008 → Dec 2013 | gestational diabetes, type 2 diabetes mellitus | Dow University of Health Sciences | Unknown | No outcome recorded |
| Phase 2/3 | NCT00362765 | Oct 2006 → Jul 2007 | hyperlipidemia, type 2 diabetes mellitus | Solvay Pharmaceuticals | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT00268476 | Jul 2005 → Mar 2026 overdue | prostate cancer | Medical Research Council | Active not recruiting | Mixed |
| Phase 2/3 | NCT01087866 | Jun 2005 → Aug 2009 | gestational diabetes | University of Oulu | Completed | Missed primary |
| Phase 2/3 | NCT00303537 | Nov 2004 → Jun 2008 | fatty liver disease | University Hospital, Aker | Unknown | Missed primary |
| Phase 2/3 | NCT04148183 | Jan 2004 → Jan 2005 | — | J JESUS VENEGAS, MD | Completed | No outcome recorded |
| Phase 2/3 | NCT00209482 | Oct 2003 → Nov 2007 | obesity disorder | Glaser Pediatric Research Network | Unknown | Met primary |
| Phase 3147 trials · 20 met primary · 19 missed | ||||||
| Phase 3 | NCT07520110 | Sep 2026 → Mar 2029 expected | idiopathic pulmonary fibrosis | University of Massachusetts, Worcester | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06405178 | Mar 2026 | polycystic ovary syndrome | Beni-Suef University | Completed | No outcome recorded |
| Phase 3 | NCT07630779 | Mar → Sep 2026 overdue | polycystic ovary syndrome | Beni-Suef University | Recruiting | No outcome recorded |
| Phase 3 | NCT07136987 | Jan 2026 → Jan 2031 expected | tuberculosis | Open Source Pharma Foundation | Not yet recruiting | Missed primary |
| Phase 3 | NCT07120815 | Sep 2025 → Dec 2027 expected | polycystic ovary syndrome | Helsinki University Central Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06999343 | Sep 2025 → May 2029 expected | chronic obstructive pulmonary disease | Fundación Instituto de Investigación Sanitaria de Navarra | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07297290 | Jul 2025 → Mar 2027 expected | obesity disorder | University Of Nigeria Teaching Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT07475546 | Jul 2025 → Apr 2026 overdue | — | AgelessRx | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06836128 | Mar 2025 → Feb 2026 overdue | polycystic ovary syndrome | Cairo University | Recruiting | No outcome recorded |
| Phase 3 | NCT07280572 | Feb 2025 → Dec 2027 expected | post-COVID-19 disorder | Janneke van de Wijgert | Enrolling by invitation | No outcome recorded |
| Show all 147 trials opens the full record — a long page | ||||||
| Phase 4218 trials · 25 met primary · 14 missed | ||||||
| Phase 4 | NCT07027969 | Nov 2026 → Dec 2029 expected | atrial fibrillation, obesity disorder | Ali Aminian | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07811856 | Aug 2026 | polycystic ovary syndrome | Jerash Private University | Completed | No outcome recorded |
| Phase 4 | NCT07696806 | Jul 2026 → Jun 2027 expected | hyperpigmentation of the skin | Sameh Sarsik | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT07485764 | Jun 2026 overdue | obesity disorder, psoriasis | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07323381 | Dec 2025 → Sep 2027 expected | type 2 diabetes mellitus | Bin Lu | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06862739 | Oct 2025 → Apr 2026 overdue | type 2 diabetes mellitus | Nabiqasim Industries (Pvt) Ltd | Recruiting | No outcome recorded |
| Phase 4 | NCT07442006 | Oct 2025 → Mar 2027 expected | type 2 diabetes mellitus | JW Pharmaceutical | Recruiting | No outcome recorded |
| Phase 4 | NCT06707012 | Oct 2025 → Jun 2026 overdue | depressive disorder | Fazaia Ruth Pfau Medical College | Recruiting | No outcome recorded |
| Phase 4 | NCT07793838 | Aug 2025 → Feb 2026 | polycystic ovary syndrome | Jerash Private University | Completed | No outcome recorded |
| Phase 4 | NCT04523363 | Jun 2025 → Jun 2026 | prediabetes syndrome | Gianna Wilkie | Withdrawn | No outcome recorded Stop: Business |
| Show all 218 trials opens the full record — a long page | ||||||
| Phase not applicable142 trials · 2 met primary · 4 missed | ||||||
| — | NCT07867236 | Oct 2026 → Sep 2027 expected | odontogenic cyst | Fayoum University | Not yet recruiting | No outcome recorded |
| — | NCT07495748 | Jul → Dec 2026 expected | hyperpigmentation of the skin | Foundation University Islamabad | Not yet recruiting | No outcome recorded |
| — | NCT07485777 | Jul → Dec 2026 expected | hyperpigmentation of the skin | Foundation University Islamabad | Not yet recruiting | No outcome recorded |
| — | NCT07654179 | Jun 2026 → Jun 2027 expected | depressive disorder, obesity disorder | Riphah International University | Recruiting | No outcome recorded |
| — | NCT07589387 | May 2026 → Apr 2029 expected | diabetes mellitus | Washington University School of Medicine | Not yet recruiting | No outcome recorded |
| — | NCT07497568 | Nov 2025 → Mar 2027 expected | — | University of Baghdad | Recruiting | No outcome recorded |
| — | NCT07215156 | Oct 2025 → Apr 2026 overdue | chronic periodontitis | Kafrelsheikh University | Not yet recruiting | No outcome recorded |
| — | NCT06907472 | Sep 2025 → Jun 2026 overdue | type 2 diabetes mellitus | University of Abuja | Active not recruiting | No outcome recorded |
| — | NCT07108075 | Jun → Oct 2025 overdue | cirrhosis of liver | Institute of Liver and Biliary Sciences, India | Recruiting | No outcome recorded |
| — | NCT06965868 | Jun 2025 → Feb 2027 expected | mental disorder | Leibniz Institute for Resilience Research | Not yet recruiting | No outcome recorded |
| Show all 142 trials opens the full record — a long page | ||||||
| Comparator or background therapy904 trials | ||||||
| Phase 0 | NCT07209527 Background | Oct 2025 → Oct 2028 expected | abdominal obesity-metabolic syndrome, chronic kidney disease, hyperlipidemia, hypertensive disorder +3 | Truway Health, Inc. | Enrolling by invitation | No outcome recorded |
| Phase 0 | NCT05917587 Comparator | Sep 2024 → Dec 2027 expected | gestational diabetes | Anna Stanhewicz, PhD | Recruiting | No outcome recorded |
| Phase 0 | NCT06452511 Comparator | Aug 2024 → Mar 2025 | polycystic ovary syndrome | Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy | Completed | No outcome recorded |
| Phase 0 | NCT06772857 Background | Jul → Aug 2024 overdue | — | Cairo University | Active not recruiting | No outcome recorded |
| Phase 0 | NCT05515978 Comparator | Oct 2022 → Oct 2035 expected | prostate cancer | University of Colorado, Denver | Recruiting | No outcome recorded |
| Show all 904 trials opens the full record — a long page | ||||||
Press releases naming this drug 86 releases
Evidence & citations 66 cited values
Every value below carries the sentence it was read from. 2,105 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Metformin | “Subjects will be randomized 1:1 to open-label eucaloric very-low carbohydrate ketogenic diet (<40 g of carbohydrate) or standard of care (i.e. metformin, followed by...” NCT07866846 ↗2017“Besides the glucose lowering effect by reducing hepatic glucose output and improving insulin resistance, metformin without inhibiting DPP-4 activity,also increases active GLP-1...” NCT02188186 ↗ “In addition to the routine treatment (metformin), patients will receive a second drug orally for 12 weeks: the METV group will receive metformin plus vildagliptin (50 mg twice...” PMID 25366037 ↗ Nov 2014 “The secondary objective is to assess in healthy Chinese subjects, the safety and tolerability of the SHR3824 and Metformin after single doses (administered in the fed and...” NCT05120219 ↗ “This study aimed to evaluate the treatment efficacy of dapagliflozin and metformin, alone and in combination, on body weight and anthropometric, cardiovascular, and metabolic...” PMID 33345876 ↗ May 2020 “Metformin 500 mg BID with breakfast and dinner. After 3 days, if no (GI) intolerance, increase to 1000 mg BID with breakfast and dinner. If not tolerated, reduce to prior...” NCT04300790 ↗ “A Single-Dose, Open-Label, Randomized, 2-Period Crossover Study to Assess the Effect of Food Coadministration on the Pharmacokinetics of a Fixed Dose Combination Tablet of...” NCT02039258 ↗ “Day 21: Single oral dose of a cocktail of cytochrome P450 substrates (caffeine 100 mg, midazolam 2 mg, and omeprazole 20 mg) along with transporter substrate (metformin 500 mg)...” NCT05657613 ↗ “Step 1: Metformin 500 mg daily Step 2: Metformin 1000 mg daily Step 3: Metformin 1000 mg twice daily Step 4: Metformin 1000 mg twice daily + glibenclamide 5 mg daily Step 5:...” NCT06907472 ↗ “Dapagliflozin/Metformin Tablet (5 mg/850 mg) Relative to a 5 mg Dapagliflozin Tablet and an 850 mg Metformin (Glucophage® Marketed in Canada by Sanofi-Aventis) Tablet...” NCT01535677 ↗ “The hypoglycemic scheme of the experimental group was that the initial dose of Insulin Degludec and Insulin Aspart was 0.3U/kg multiplied by the patient's weight, plus 5 mg of...” NCT05641337 ↗ |
| Known as | 1,1-dimethylbiguanide | “Metformin, 1,1 dimethylbiguanide, or systematic (IUPAC) name N,N-dimethylimidodicarbonimidic diamide, is an oral anti-diabetic medicine approved in the US by the FDA in 1994.” NCT04141163 ↗2“Metformin's chemical name is 1,1-Dimethylbiguanide, a molecular formula of C4H11N5.” NCT07055958 ↗ “Metformin (1,1-dimethylbiguanide) is an oral antihyperglycemic drug.” NCT05468554 ↗ |
| Known as | 1,1-dimethylbiguanide hydrochloride | “Testing for Atypia in Random Periareolar Fine Needle Aspiration (RPFNA) Cytology After 12 Months Metformin (1, 1-Dimethylbiguanide Hydrochloride) Chemoprevention Versus Placebo...” NCT01905046 ↗2“Metformin (1,1-dimethylbiguanide hydrochloride) is an FDA-approved, first-line oral hypoglycemic agent utilized globally for the management of Type II Diabetes Mellitus.” NCT07867236 ↗ “Metformin (1,1-dimethylbiguanide hydrochloride) belongs to the biguanide class of oral hypoglycaemic agents” NCT00881725 ↗ |
| Known as | A10BA02 Metformin | “A10BA02 Metformin” NCT01690091 ↗ |
| Known as | Cidophage | “Metformin 1000 mg (Cidophage® 1000 mg tablets, CID, Giza, Egypt) tablet twice daily for 6 months as add on therapy with Interferon beta 1 a (Rebiff ® 44mcg or Avonex ®).” NCT06812585 ↗6“All patients in the combined metformin-CC group received metformin HCl (Cidophage®;Chemical Industries Development,Cairo, Egypt), 500 mg thrice daily for 6-8 weeks.” NCT00969631 ↗ “Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt) 500 mg twice daily will also started from day 3 till the date of doing pregnancy test” NCT05362799 ↗ “Metformin 1000 mg (Cidophage® 1000 mg tablets, CID, Giza, Egypt) tablet twice daily for 6 months as add on therapy” NCT05298670 ↗ “wMetformin (Cidophage , Amon , Egypt) 500 mg twice daily continuously for three cycles.” NCT02562664 ↗ “metformin HCl (Cidophage®; Chemical Industries Development, Egypt)” NCT01008046 ↗ “metformin HCl (Cidophage®; CID,Cairo, Egypt)” NCT00911313 ↗ |
| Known as | CLUCOPHAGE XR | “The purpose of this study is to compare the relative bioavailability of 500 mg Metformin Hydrochloride Extended Release Tablets by Purepac Pharmaceutical Co. with that of 500...” NCT00865839 ↗ |
| Known as | Diabex | “It is marketed alone under the names metformin (generic), Glucophage XR, Riomet, Fortamet, Glumetza, Obimet, Gluformin, Dianben, Diabex, and Diaformin and in combination with...” NCT04141163 ↗1“metformin 1500mg plus metformin 500mg or 1000mg (Diabex)” NCT00975065 ↗ |
| Known as | Diaformin | “It is marketed alone under the names metformin (generic), Glucophage XR, Riomet, Fortamet, Glumetza, Obimet, Gluformin, Dianben, Diabex, and Diaformin and in combination with...” NCT04141163 ↗ |
| Known as | Dianben | “It is marketed alone under the names metformin (generic), Glucophage XR, Riomet, Fortamet, Glumetza, Obimet, Gluformin, Dianben, Diabex, and Diaformin and in combination with...” NCT04141163 ↗ |
| Known as | dimethylbiguanide | “The antihyperglycemic drug dimethylbiguanide (DMB, also known as metformin) reduces the risk of cardiovascular complications in type 2 diabetes” PMID 11756340 ↗ Jan 2002 |
| Known as | DMB | “The antihyperglycemic drug dimethylbiguanide (DMB, also known as metformin) reduces the risk of cardiovascular complications in type 2 diabetes” PMID 11756340 ↗ Jan 2002 |
| Known as | EFB0026 | “EFB0026 (metformin immediate-release)” NCT01677299 ↗ |
| Known as | EFB0027 | “delayed-release metformin (Met DR, EFB0027) at two dosage levels, immediate-release metformin (Met IR, ETB0015), and extended-release metformin (Met XR, ETB0014)” NCT02291510 ↗1“EFB0027 (metformin delayed release)” NCT01677299 ↗ |
| Known as | ETB0014 | “delayed-release metformin (Met DR, EFB0027) at two dosage levels, immediate-release metformin (Met IR, ETB0015), and extended-release metformin (Met XR, ETB0014)” NCT02291510 ↗ |
| Known as | ETB0015 | “delayed-release metformin (Met DR, EFB0027) at two dosage levels, immediate-release metformin (Met IR, ETB0015), and extended-release metformin (Met XR, ETB0014)” NCT02291510 ↗ |
| Known as | Fortamet | “A new medicine called exenatide (Byetta) has been found to reduce body weight, as well as, improve abnormal glucose metabolism in diabetics. This randomized study will compare...” NCT00344851 ↗1“It is marketed alone under the names metformin (generic), Glucophage XR, Riomet, Fortamet, Glumetza, Obimet, Gluformin, Dianben, Diabex, and Diaformin and in combination with...” NCT04141163 ↗ |
| Known as | Glifage | “850mg of metformin hydrochloride (HCl) (Glifage®) tablet” NCT05083949 ↗ |
| Known as | GLUCOLIFE XR 500 | “The prolonged release metformin tablets 500 mg (Brand Name: GLUCOLIFE XR ® 500) will be provided by QLife Pharma manufacturer, Doha, Qatar.” NCT07622290 ↗ |
| Known as | glucophage | “Dapagliflozin/Metformin Tablet (5 mg/850 mg) Relative to a 5 mg Dapagliflozin Tablet and an 850 mg Metformin (Glucophage® Marketed in Canada by Sanofi-Aventis) Tablet...” NCT01535677 ↗31“Metformin hydrochloride (Glucophage®, National Medicine Standard No. H20023370, Shanghai Bristol-Myers Squibb Pharmaceuticals Co., Ltd.) was administered at a dose of 0.5 g...” NCT07687667 ↗ “A Randomized Open-label, Repeat Dose, Two Sequence Cross-Over Study to Determine the Effect of GSK189075 on the Pharmacokinetic Parameters of Metformin (Glucophage) in Subjects...” NCT00376038 ↗ “IRMCI-2 (diabetic patients): Active Intervention (Intensive lifestyle modification) plus metformin (Glucophage, 250mg thrice daily) or Control group (standard lifestyle...” NCT02409238 ↗ “Metformin, sold under the brand name Glucophage, among others, is the main first-line medication for the treatment of type 2 diabetes, particularly in people who are overweight.” NCT07229651 ↗ “The groups are: 1) a lifestyle modification program plus metformin (also known as glucophage), 2) lifestyle modification plus placebo, 3) metformin alone or 4) placebo alone.” NCT00399360 ↗ “Drug: Glucophage Generic name: Metformin Dosage form: 500mg Dosage: 1500-2000mg/day Frequency: 500mg three times a day/1000mg twice a day Duration: 3 months” NCT04969627 ↗ “Metformin hydrochloride (Glucophage®, National Medicine Standard No. H20023370, Shanghai Bristol-Myers Squibb Pharmaceuticals Co., Ltd.)” NCT06775093 ↗ “Metformin (Glucophage; Bristol-Myers Squibb, Princeton, NJ) is an insulin sensitizer and lowers serum insulin and androgen levels.” NCT00413179 ↗ “Participants were only subjected to use Glucophage 500mg 30 minutes before breakfast for the duration of 02 months.” NCT07586969 ↗ “the patients with 25kg/m2\<BMI≤35kg/m2 were initiated with Metformin (Glucophage, BMS) 0.5 Bid (maximum to 2.0g/d)” NCT00147836 ↗ |
| Known as | Glucophage 1000 | “The chosen posology is 2540 mg/day of metformin-base so 3 tablets/day of Glucophage ® 1000.” NCT01840007 ↗ |
| Known as | GLUCOPHAGE Sustained Release | “commercially available formulations of metformin extended release (XR) (GLUCOPHAGE ™ Sustained Release” NCT01725672 ↗ |
| Known as | Glucophage (metformin hydrochloride) | “Glucophage (metformin hydrochloride)” NCT05900466 ↗ |
| Known as | Glucophage (Metformin) | “Glucophage (Metformin)” NCT03010683 ↗ |
| Known as | Glucophage SR | “The RenoMet trial is repurposing an already approved agent (Metformin , Glucophage SR ) in a new indication (renoprotection )” NCT03831464 ↗1“Atorvastatin (Lipitor) and Metformin (Glucophage SR)” NCT02378441 ↗ |
| Known as | Glucophage XR | “It is marketed alone under the names metformin (generic), Glucophage XR, Riomet, Fortamet, Glumetza, Obimet, Gluformin, Dianben, Diabex, and Diaformin and in combination with...” NCT04141163 ↗6“patients will be treated with metformin extended release (ER) (Glucophage® XR), starting at 750 milligrams (mg) oral (PO) once daily (QD) for 4 days, then escalating to 750 mg...” NCT03477162 ↗ “The metformin arm will be consuming Glucophage XR (metformin hydrochloride extended release, 750 or 500 mg, encapsulated in #00 opaque capsules for 4 weeks according to the...” NCT02179788 ↗ “Glucophage XR 750 mg once at dinner for 15 days then twice daily” NCT06045351 ↗ “GLUCOPHAGE® XR 750 mg tablets, single dose” NCT00865852 ↗ |
| Known as | Glucophage XR (metformin hydrochloride) | “Glucophage XR (metformin hydrochloride)” NCT05900466 ↗ |
| Known as | Glucophage XR 1000mg(Metformin) | “Glucophage XR 1000mg(Metformin)” NCT01992211 ↗ |
| Known as | Glucophage, Metformin HCl | “Glucophage, Metformin HCl” NCT01486043 ↗ |
| Known as | GlucophageXR/SR 500 | “Metformin is administered as Glucophage®XR/SR 500, (500 mg oral tablets).” PMID 38297399 ↗ Jan 2024 |
| Known as | Gluformin | “It is marketed alone under the names metformin (generic), Glucophage XR, Riomet, Fortamet, Glumetza, Obimet, Gluformin, Dianben, Diabex, and Diaformin and in combination with...” NCT04141163 ↗ |
| Known as | Glumetza | “It is marketed alone under the names metformin (generic), Glucophage XR, Riomet, Fortamet, Glumetza, Obimet, Gluformin, Dianben, Diabex, and Diaformin and in combination with...” NCT04141163 ↗1“2x500 mg Metformin (Glumetza)” NCT01845077 ↗ |
| Known as | MET | “Canagliflozin (CANA), a kind of sodium-glucose cotransporter-2 (SGLT-2) inhibition, study in which the role of CANA monotherapy in polycystic ovary syndrome (PCOS) has been...” PMID 36147577 ↗ Sep 202225“The aim of the present study was to evaluate the effects of commonly used treatment regimens such as metformin (MET) or an oral contraceptive pill (OC) containing...” PMID 24554512 ↗ Feb 2014 “Although metformin (MET) is an insulin sensitizer currently used as an adjunct to the treatment of some of the complications of childhood obesity besides type 2 diabetes...” PMID 18761646 ↗ Aug 2008 “The purpose of this study is to assess the effect of coadministration of a high-fat meal on the oral bioavailability of a fixed dose combination of Canagliflozin/extended...” NCT02039258 ↗ “The overarching hypothesis of this study is that vildagliptin (vilda) as add on therapy to metformin (met) in Egyptian type 2 diabetic obese patient will produce an equal, if...” NCT07077525 ↗ “The aim of this trial was to evaluate the efficacy and safety of the combination of once-daily insulin detemir (IDet) and sitagliptin (SITA) versus SITA ± sulphonylurea (SU),...” PMID 21205123 ↗ Mar 2011 “twice-daily biphasic insulin aspart 30 (30% soluble and 70% protaminated insulin aspart; BIAsp 30) plus metformin (met) was compared with once-daily insulin glargine (glarg)...” PMID 17115351 ↗ Oct 2006 “OBJECTIVE: To determine if the combination of lifestyle (caloric restriction and exercise) and metformin (MET) would be superior to lifestyle and placebo (PBO) in improving the...” PMID 21193187 ↗ Dec 2010 “we evaluated exenatide (EX) and metformin (MET), alone and in combination (COM), on menstrual cyclicity, hormonal parameters, metabolic profiles, and inflammatory markers in...” PMID 18460557 ↗ May 2008 “Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination...” NCT01068652 ↗ “Participants were randomly assigned (1:1) to the healthy eating and physical activity (LIFE) or the metformin plus LIFE (MET plus LIFE) interventions, within eight strata...” PMID 41233082 ↗ Dec 2025 |
| Known as | Met DR | “This study compared the effect of delayed-release metformin (Met DR) to placebo and extended release metformin (Met XR) on glycemic control (fasting plasma glucose and HbA1c)...” NCT01819272 ↗3“This study compared the effects of delayed-release metformin (Met DR, EFB0027) administered once daily in the morning (qAM), administered once daily in the evening (qPM), and...” NCT01804842 ↗ “delayed-release metformin (Met DR, EFB0027) at two dosage levels, immediate-release metformin (Met IR, ETB0015), and extended-release metformin (Met XR, ETB0014)” NCT02291510 ↗ “single dose of delayed-release metformin (Met DR)” NCT01658514 ↗ |
| Known as | Met IR | “delayed-release metformin (Met DR, EFB0027) at two dosage levels, immediate-release metformin (Met IR, ETB0015), and extended-release metformin (Met XR, ETB0014)” NCT02291510 ↗1“immediate-release metformin (Met-IR)” NCT02791490 ↗ |
| Known as | Met XR | “This study compared the effect of delayed-release metformin (Met DR) to placebo and extended release metformin (Met XR) on glycemic control (fasting plasma glucose and HbA1c)...” NCT01819272 ↗2“delayed-release metformin (Met DR, EFB0027) at two dosage levels, immediate-release metformin (Met IR, ETB0015), and extended-release metformin (Met XR, ETB0014)” NCT02291510 ↗ “extended-release metformin (Met XR)” NCT01658514 ↗ |
| Known as | Metfor 500 mg, Metformin hydrochloride tablets. TABUK Pharmaceutical. KSA | “Metfor® 500 mg, Metformin hydrochloride tablets. TABUK Pharmaceutical. KSA” NCT04852510 ↗ |
| Known as | metformin (Glucophage) | “metformin (Glucophage)” NCT00000620 ↗ |
| Known as | Metformin ER | “Metformin ER, one gram three times daily taken orally.” NCT06033131 ↗ |
| Known as | Metformin Glycinate | “Metformin Glycinate is a novel biguanide compound developed as a potential candidate for the treatment of type 2 diabetes.” NCT01560481 ↗ |
| Known as | Metformin Hcl | “A Phase 3b, Double-Blind, Randomized Study to Determine the Efficacy and Safety of Pioglitazone HCl and Metformin HCl Fixed-Dose Combination Therapy Compared to Pioglitazone...” NCT00727857 ↗30“One or two Metformin HCl tablets 850 mg (depending on tolerability) and 6 colesevelam 625 mg tablets once daily for 16 weeks” NCT00570739 ↗ “test formulation of Metformin HCl 1000 mg granules manufactured by Indeus Life Sciences Pvt. Ltd., Mumbai India” NCT02217670 ↗ “Metformin HCl 500mg tablets contain 500mg of active pharmaceutical ingredient (API)” NCT05230758 ↗ “Reference products : Metformin HCl 500mg tablet, Repaglinide 2mg tablet” NCT01780051 ↗ “Tablet Metformin HCl 500 mg per oral twice daily for 12 weeks” NCT05759442 ↗ “Metformin Hcl 500Mg 24Hr Sa Tab drug is given to the patient” NCT03684707 ↗ “Metformin HCl 750 mg Extender Release tablets, single dose” NCT00865852 ↗ “Metformin HCl 750 mg Extender Release tablets, single dose” NCT00865072 ↗ “metformin HCl extended release 1000 mg (500mg x 2 tablets)” NCT03355014 ↗ “Lobeglitazone Sulfate 0.5mg, Metformin HCl 1500mg” NCT02627027 ↗ |
| Known as | metformin HCl extended release | “Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg, for 1 day” NCT01662674 ↗ |
| Known as | Metformin Hydrochloride | “This is a phase-1, single center, open-label, randomized, single-dose, 2-way crossover study. The objective of the study is to compare the pharmacokinetic properties after...” NCT01780051 ↗113“The purpose of this study is to compare the relative bioavailability of 500 mg Metformin Hydrochloride Extended Release Tablets by Purepac Pharmaceutical Co. with that of 500...” NCT00865839 ↗ “The Effect of Alogliptin Combined With Pioglitazone and Metformin Hydrochloride Tablets on Glucose and Lipid Metabolism and Islet Function in Patients With Type 2 Diabetes...” NCT07289750 ↗ “Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of...” NCT00570739 ↗ “Metformin hydrochloride (Glucophage®, National Medicine Standard No. H20023370, Shanghai Bristol-Myers Squibb Pharmaceuticals Co., Ltd.) was administered at a dose of 0.5 g...” NCT07687667 ↗ “Patients randomized to metformin treatment will take 750 mg Metformin Hydrochloride tablets once daily for 4 weeks; the dose will be increased to 750 mg twice daily for the...” NCT05426044 ↗ “Metformin hydrochloride 500 mg tablet once daily starting one week after the initiation of TB treatment, then increasing to twice daily through study week-12 (11 weeks total...” NCT04930744 ↗ “The metformin arm will be consuming Glucophage XR (metformin hydrochloride extended release, 750 or 500 mg, encapsulated in #00 opaque capsules for 4 weeks according to the...” NCT02179788 ↗ “Standard therapy includes valsartan capsules 80 mg orally once daily, metformin hydrochloride tablets 0.5 g orally three times daily, and atorvastatin calcium tablets 10 mg...” NCT07702669 ↗ “Metformin hydrochloride is a white to off-white crystalline compound formulated as tablets for oral consumption; tablets contain 500 mg, 850 mg, or 1000 mg of metformin hydrochloride.” NCT02659306 ↗ “This phase III trial studies how well metformin hydrochloride works compared to placebo in preventing breast cancer in patients with atypical hyperplasia or in situ breast cancer.” NCT01905046 ↗ |
| Known as | metformin hydrochloride (HCl) | “The subjects randomly received single oral dose of Sitagliptin/metformin hydrochloride (HCl) 50/1000 mg film-coated tablet” NCT05549583 ↗2“Metformin hydrochloride (HCl) 500mg tablet” NCT05230758 ↗ “Drug: Metformin Hydrochloride (HCL)” NCT05759442 ↗ |
| Known as | Metformin hydrochloride branded as Glucophage | “Metformin hydrochloride branded as Glucophage” NCT01638676 ↗ |
| Known as | MetFORMIN Hydrochloride ER | “Subjects will be exposed to 500mg of daily MetFORMIN Hydrochloride ER for up to 90 days.” NCT03772964 ↗ |
| Known as | Metformin Hydrochloride Extended-release Tablets | “The metformin utilized in this study is Metformin Hydrochloride Extended-release Tablets, manufactured by Bristol-Myers Squibb Company.” NCT06762223 ↗ |
| Known as | Metformin IR | “Single dose (1000 mg) of metformin IR” NCT05151146 ↗ |
| Known as | Metformin SR | “Crestor 10mg(Rosuvastatin 10mg), Glucodown OR SR 750mg(Metformin SR 750mg)” NCT01526317 ↗ |
| Known as | metformin sustained release | “A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in...” PMID 25678778 ↗ Feb 2015 |
| Known as | Metformin XR | “Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8...” NCT01234649 ↗11“Two FDC tablets of gemigliptin/metformin 25/500 mg or separate tablets of gemigliptin (50 mg ×1) and metformin XR (500 mg ×2) were orally administered in each period.” PMID 25678778 ↗ Feb 2015 “Metformin XR (tablets) administered at a starting dose of 500mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 days cycle.” NCT04899349 ↗ “Participants in the Treatment Arm will receive oral extended-release metformin (metformin-XR) 1x daily with an evening meal starting prior to conception.” NCT07129473 ↗ “Metformin tablets (Metformin XR, extended release 500 mg, oral tablet, active ingredient: metformin hydrochloride).” NCT07622290 ↗ “Metformin XR capsules, 1000 mg, one per day before breakfast during 12 weeks.” NCT03710460 ↗ “Dapagliflozin (5 mg) + Metformin XR (up to 2000 mg)” NCT00643851 ↗ “1 Metformin XR caplet 750 mg (twice daily)” NCT01733459 ↗ “Metformin XR, 500-2000mg nocte” NCT04511416 ↗ “Metformin XR 1500 mg” NCT00918138 ↗ “Drug: Metformin XR” NCT02145559 ↗ |
| Known as | metformin(diabex) | “metformin(diabex)” NCT00474838 ↗ |
| Known as | Metformin: Fortamet, Glucophage | “Metformin: Fortamet, Glucophage” NCT01968317 ↗ |
| Known as | metformine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02523898 ↗ |
| Known as | metformine HCl | “Active Substance: Glimepiride/metformine HCl 2 mg/1000 mg” NCT02395237 ↗ |
| Known as | Metformini hydrochloridum | “Metformini hydrochloridum (Siofor 1000 tbl, Berlin)” NCT01690091 ↗ |
| Known as | MTF | “Metformin (MTF), a biguanide, usually used in obese patients with type 2 diabetes,inhibits glucose hepatic production,decreases insulin secretion and increases peripheral...” NCT00679679 ↗1“DZX + metformin (DZX + MTF)” PMID 30202851 ↗ Nov 2018 |
| Known as | MXR | “combination with metformin extended release (MXR) or placebo” PMID 27433488 ↗ Nov 2014 |
| Known as | N dimethyl-biguanide | “Metformin (N dimethyl-biguanide) is an anti diabetic drug that increases glucose utilization in insulin sensitive tissues.” NCT01279512 ↗ |
| Known as | N,N-dimethylimidodicarbonimidic diamide | “Metformin, 1,1 dimethylbiguanide, or systematic (IUPAC) name N,N-dimethylimidodicarbonimidic diamide, is an oral anti-diabetic medicine approved in the US by the FDA in 1994.” NCT04141163 ↗ |
| Known as | Obimet | “It is marketed alone under the names metformin (generic), Glucophage XR, Riomet, Fortamet, Glumetza, Obimet, Gluformin, Dianben, Diabex, and Diaformin and in combination with...” NCT04141163 ↗ |
| Known as | Riomet | “It is marketed alone under the names metformin (generic), Glucophage XR, Riomet, Fortamet, Glumetza, Obimet, Gluformin, Dianben, Diabex, and Diaformin and in combination with...” NCT04141163 ↗ |
| Known as | Siofor 1000 tbl, Berlin | “Metformini hydrochloridum (Siofor 1000 tbl, Berlin)” NCT01690091 ↗ |
| Action | Activate | “the therapeutic effects of the drug, which involve activation of AMP-activated protein kinase (AMPK), is unknown.” PMID 17476361 ↗ May 2007 |
| Modality | Small molecule | “Metformin is still the recommended first-line glucose-lowering drug for people with T2DM.” PMID 32501595 ↗ Jun 2020 |
| Route | Oral | “Patients receive oral metformin or oral placebo three times daily for 7 weeks” NCT00005104 ↗ |
| Target | MTOR | “It may be able to block mTOR and slow the growth of tumors.” NCT01087983 ↗ |